Boston Scientific's recall of 500 of its Innova stents from overseas customers, after receiving complaints that the devices can fail to deploy or only partially deploy, is given the FDA's most serious Class I designation.

The FDA made a May recall by Boston Scientific Corp. (NYSE:BSX) of 500 of its Innova stents from customers overseas Class I, its most serious designation.
It's the second Class I recall for the Natick, Mass.-based medical device giant posted last month, after pulling all 30,000 of its iCross coronary catheters.
Pluristem is seeking clinical proof that stem cell therapy can benefit patients with chronic...
GE Healthcare introduces Mavric SL, a novel magnetic resonance imaging technique for joint...
Johnson & Johnson subsidiary DePuy Orthopaedics plans to phase out sales of all of its metal-on-...
The FDA approves a novel combat-ready clamp to treat wounds most commonly associated with roadside or...
Vascular Solutions CEO Howard Root says alleged infringement by Boston Scientific's Guidezilla "is...